Flavonoids and the Risk of Gastric Cancer: An Exploratory Case-Control Study in the MCC-Spain Study.
MCC-Spain
case-control study
flavonoids
gastric cancer
intake
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
27 Apr 2019
27 Apr 2019
Historique:
received:
16
03
2019
revised:
19
04
2019
accepted:
24
04
2019
entrez:
1
5
2019
pubmed:
1
5
2019
medline:
30
11
2019
Statut:
epublish
Résumé
Several epidemiological studies have investigated the association between the dietary flavonoid intake and gastric cancer (GC) risk; however, the results remain inconclusive. Investigating the relationship between the different classes of flavonoids and the histological types and origin of GC can be of interest to the research community. We used data from a population-based multi-case control study (MCC-Spain) obtained from 12 different regions of Spain. 2700 controls and 329 GC cases were included in this study. Odds ratios (ORs) were calculated using the mixed effects logistic regression considering quartiles of flavonoid intakes and log2. Flavonoid intake was associated with a lower GC risk (ORlog2 = 0.76; 95% CI = 0.65-0.89; ORq4vsq1 = 0.60; 95%CI = 0.40-0.89; ptrend = 0.007). Inverse and statistically significant associations were observed with anthocyanidins, chalcones, dihydroflavonols and flavan-3-ols. The isoflavanoid intake was positively associated with higher cancer risk, but without reaching a statistical significance. In general, no differences were observed in the GC risk according to the location and histological type. The flavonoid intake seems to be a protective factor against GC within the MCC-study. This effect may vary depending on the flavonoid class but not by the histological type and location of the tumor. Broader studies with larger sample size and greater geographical variability are necessary.
Identifiants
pubmed: 31035601
pii: nu11050967
doi: 10.3390/nu11050967
pmc: PMC6566880
pii:
doi:
Substances chimiques
Flavonoids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Nutr. 2000 Aug;130(8S Suppl):2073S-85S
pubmed: 10917926
J Nutr. 2004 Dec;134(12 Suppl):3479S-3485S
pubmed: 15570057
In Vivo. 2005 Sep-Oct;19(5):895-909
pubmed: 16097445
J Nutr Biochem. 2007 Jul;18(7):427-42
pubmed: 17321735
Eur J Cancer Prev. 2007 Aug;16(4):312-27
pubmed: 17554204
Eur J Cancer. 2007 Jul;43(11):1731-40
pubmed: 17596928
Mol Carcinog. 2009 Mar;48(3):260-270
pubmed: 18729103
Cell Cycle. 2008 Nov 1;7(21):3320-6
pubmed: 18948740
Am J Clin Nutr. 2009 May;89(5):1553S-1557S
pubmed: 19297461
Am J Clin Nutr. 2009 May;89(5):1441-52
pubmed: 19339391
Database (Oxford). 2010;2010:bap024
pubmed: 20428313
Nutr Cancer. 2010;62(4):505-16
pubmed: 20432172
Int J Mol Sci. 2010 Mar 31;11(4):1321-42
pubmed: 20480022
Cancer Causes Control. 2010 Oct;21(10):1597-604
pubmed: 20521092
Ann Oncol. 2011 Feb;22(2):438-43
pubmed: 20688844
Br J Cancer. 2011 Jan 4;104(1):6-11
pubmed: 21119663
Free Radic Biol Med. 2011 May 15;50(10):1324-35
pubmed: 21277973
Int J Oncol. 2011 May;38(5):1403-8
pubmed: 21344159
IARC Monogr Eval Carcinog Risks Hum. 2010;96:3-1383
pubmed: 21735939
Am J Clin Nutr. 2012 Jan;95(1):147-54
pubmed: 22170362
Br J Nutr. 2013 Apr 28;109(8):1498-507
pubmed: 22980437
Am J Clin Nutr. 2012 Dec;96(6):1398-408
pubmed: 23076618
Expert Opin Drug Metab Toxicol. 2013 Mar;9(3):267-85
pubmed: 23289831
Ann Oncol. 2013 Jun;24(6):1450-8
pubmed: 23524862
Cancer Treat Res. 2014;159:35-50
pubmed: 24114473
Tumour Biol. 2014 Aug;35(8):7719-26
pubmed: 24805829
Biochem Soc Trans. 2014 Aug;42(4):1017-23
pubmed: 25109996
Nutrients. 2014 Nov 10;6(11):4961-73
pubmed: 25389898
Oncol Rep. 2015 Feb;33(2):868-74
pubmed: 25500692
Gac Sanit. 2015 Jul-Aug;29(4):308-15
pubmed: 25613680
Int J Cancer. 2015 Aug 15;137(4):885-92
pubmed: 25639758
Br J Cancer. 2015 Mar 31;112(7):1291-300
pubmed: 25668011
BMJ. 2015 Feb 10;350:h384
pubmed: 25670624
Gut. 2015 Dec;64(12):1881-8
pubmed: 25748648
Am J Clin Nutr. 2015 Jun;101(6):1113-25
pubmed: 25854881
Evid Based Complement Alternat Med. 2015;2015:921306
pubmed: 25949267
Dig Dis Sci. 2015 Oct;60(10):2985-95
pubmed: 25972151
Eur J Nutr. 2016 Jun;55(4):1359-75
pubmed: 26081647
Br J Nutr. 2015 Apr;113 Suppl 2:S102-10
pubmed: 26148912
Pharmacogn Mag. 2015 Oct;11(Suppl 2):S275-83
pubmed: 26664015
Nutrients. 2016 Feb 16;8(2):91
pubmed: 26891324
Tumour Biol. 2016 Aug;37(8):11365-74
pubmed: 26960693
Sci Rep. 2016 Apr 26;6:24836
pubmed: 27112267
J Enzyme Inhib Med Chem. 2016;31(sup2):46-50
pubmed: 27233102
Fitoterapia. 2016 Jul;112:175-82
pubmed: 27242217
Toxins (Basel). 2016 Jun 30;8(7):
pubmed: 27376325
Nutrients. 2016 Sep 09;8(9):
pubmed: 27618095
Tumour Biol. 2016 Nov;37(11):14513-14536
pubmed: 27651162
Oncotarget. 2017 Feb 28;8(9):15996-16016
pubmed: 27911871
Nutrients. 2016 Dec 03;8(12):
pubmed: 27918471
Mol Nutr Food Res. 2017 Apr;61(4):
pubmed: 27943649
Biochem Pharmacol. 2017 Sep 1;139:15-23
pubmed: 28377278
Chem Rev. 2017 Jun 28;117(12):7762-7810
pubmed: 28488435
Food Chem Toxicol. 2017 Oct;108(Pt A):104-119
pubmed: 28711545
J Cell Physiol. 2018 Mar;233(3):2502-2512
pubmed: 28771720
Nutr Rev. 2017 Jun 1;75(6):405-419
pubmed: 28969358
Eur Rev Med Pharmacol Sci. 2017 Dec;21(24):5850-5858
pubmed: 29272023
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Am J Clin Nutr. 1997 Apr;65(4 Suppl):1220S-1228S; discussion 1229S-1231S
pubmed: 9094926
Eur J Clin Nutr. 1997 Oct;51(10):708-12
pubmed: 9347293